Apr 15, 2024 | Press Releases
– FDA acceptance of 4-week global registrational Phase 3 RECOVER-2 study — Two positive 4-week studies plus a 12-month long-term safety study have potential to support a New Drug Application (NDA) for brilaroxazine in schizophrenia –- Topline data...
Mar 28, 2024 | Press Releases
CUPERTINO, Calif., March 28, 2024 — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of...
Mar 26, 2024 | Press Releases
CUPERTINO, Calif., March 26, 2024 — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of...
Mar 11, 2024 | Press Releases
CUPERTINO, Calif., March 11, 2024 — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of...
Mar 7, 2024 | Press Releases
CUPERTINO, Calif., March 07, 2024 — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of...
